The full edition of the report is available at Xinhua Silk Road Database. You can click the “Table of Content” to have a general understanding of it.
Click on the button below to create your account and get immediate access to thousands of articles.
China sees advance in anti-tumor drug approval
China has seen robust growth in its number of new anti-tumor drug approvals during the 13th Five-Year Plan (2016-2020) period, according to the National Medical Products Administration (NMPA).
April01,2021
Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to silkroadweekly@xinhua.org and share your stories with more people.
Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.